ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO461

Long-COVID-19 in Hemodialysis Patients: A Prospective Study

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Han, Maggie, Renal Research Institute, New York, New York, United States
  • Wang, Lin-Chun, Renal Research Institute, New York, New York, United States
  • Ren, Sarah, Renal Research Institute, New York, New York, United States
  • Tisdale, Lela, Renal Research Institute, New York, New York, United States
  • Dong, Zijun, Renal Research Institute, New York, New York, United States
  • Nze, Chidiadi Ruth, Renal Research Institute, New York, New York, United States
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States
Background

Long-COVID (LC) is defined as persistent symptoms after COVID-19 infection. It has been reported that up to 40% of COVID-19 survivors experience LC (O’Mahoney et al. The Lancet, 2023). We aim to determine if hemodialysis (HD) patients experience LC.

Methods

HD patients diagnosed with COVID-19 via RT-PCR test were enrolled from 01 to 04 2022 from 4 clinics in New York City. COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) was administered at baseline, i.e. as soon as possible after diagnosis, and 1 and 6 months after baseline. C19-YRS also asks about pre-COVID symptoms; we used that symptom severity (SS) at baseline as comparator. While SS is graded from 0-10, 10 being the worst, global health score (GH) is reported with 10 being the best. Patient data were obtained from medical records. Paired t-tests were used examine differences in SS pre- and post- COVID-19 infection. Linear and generalized mixed models were used to examine the effect of time on continuous and discrete LC SS, respectively.

Results

We studied 16 patients (58±14 years old, HD vintage 2.7±3.4 years, 56% male, 81% Black, 19% Hispanic, no diabetic, 50 % hypertensive). Baseline C19-YRS was administered 43±23 days (range 9-108) after COVID-19 diagnosis. 5 patients were hospitalized. C19-YRS results are shown in Table 1. Compared to baseline, patients experienced significantly increased dyspnea, anxiety, and PTSD at 1 month and fatigue and inability to perform personal care at 6 months. Decreased mobility and activity of daily living were also observed, though not statistically significant. Lastly, patients reported decreased GH score at months 1 and 6 compared to baseline.

Conclusion

Following COVID-19 infection, patients report worsening LC symptoms. Further studies are warranted to investigate the long-term consequences of LC in HD patients.

Funding

  • NIDDK Support – Renal Research Institute